Protalix BioTherapeutics, Inc. 8-K

What Happened Protalix BioTherapeutics, Inc. announced via a Form 8-K filed February 11, 2026 (Item 7.01, Regulation FD Disclosure) that it posted a corporate presentation to its website. The presentation was furnished to the SEC as Exhibit 99.1 to the Current Report. The filing was signed by Dror Bashan, President and Chief Executive Officer.

Key Details

• Filing date: February 11, 2026 (Form 8-K, Item 7.01 Regulation FD Disclosure).
• Corporate presentation furnished as Exhibit 99.1 to the 8-K.
• Report signed by Dror Bashan, President & CEO of Protalix BioTherapeutics.
• The filing also included the interactive cover page XBRL file (Exhibit 104).

Why It Matters This filing is a public disclosure under Regulation FD, meaning Protalix made the presentation available to the public and the SEC to ensure broad, fair access to the information. For investors, the 8-K itself does not report earnings, financial results, executive changes, or material transactions — it simply notifies that new corporate presentation materials are available. Investors who want current corporate strategy, program updates, or slides referenced should review the posted presentation directly.